中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2015年
16期
96-98
,共3页
朱少萍%罗小茶%黄慧文%林小凤%梁金兴
硃少萍%囉小茶%黃慧文%林小鳳%樑金興
주소평%라소다%황혜문%림소봉%량금흥
曼月乐节育环%子宫腺肌症%临床疗效
曼月樂節育環%子宮腺肌癥%臨床療效
만월악절육배%자궁선기증%림상료효
Levonorgestrel intrauterine system%Adenomyosis%Clinical efficacy
目的:探讨子宫内放置曼月乐节育环治疗子宫腺肌症的临床效果。方法选取本院2010年2月~2014年10月收治的84例子宫腺肌症患者作为研究对象,随机分为对照组和研究组,每组42例。对照组采用药物治疗,研究组采用曼月乐节育环进行治疗,比较两组治疗前后痛经改善情况、子宫体积、血清CA125、血红蛋白及临床疗效。结果研究组的治疗总有效率为88.1%,而对照组仅为69.0%,两组差异有统计学意义(P<0.05),且研究组的痛经症状、血清CA125改善情况优于对照组(P<0.05)。结论曼月乐节育环置于子宫内治疗子宫腺肌症的效果确切、安全性高,具有较高的临床推广价值。
目的:探討子宮內放置曼月樂節育環治療子宮腺肌癥的臨床效果。方法選取本院2010年2月~2014年10月收治的84例子宮腺肌癥患者作為研究對象,隨機分為對照組和研究組,每組42例。對照組採用藥物治療,研究組採用曼月樂節育環進行治療,比較兩組治療前後痛經改善情況、子宮體積、血清CA125、血紅蛋白及臨床療效。結果研究組的治療總有效率為88.1%,而對照組僅為69.0%,兩組差異有統計學意義(P<0.05),且研究組的痛經癥狀、血清CA125改善情況優于對照組(P<0.05)。結論曼月樂節育環置于子宮內治療子宮腺肌癥的效果確切、安全性高,具有較高的臨床推廣價值。
목적:탐토자궁내방치만월악절육배치료자궁선기증적림상효과。방법선취본원2010년2월~2014년10월수치적84례자궁선기증환자작위연구대상,수궤분위대조조화연구조,매조42례。대조조채용약물치료,연구조채용만월악절육배진행치료,비교량조치료전후통경개선정황、자궁체적、혈청CA125、혈홍단백급림상료효。결과연구조적치료총유효솔위88.1%,이대조조부위69.0%,량조차이유통계학의의(P<0.05),차연구조적통경증상、혈청CA125개선정황우우대조조(P<0.05)。결론만월악절육배치우자궁내치료자궁선기증적효과학절、안전성고,구유교고적림상추엄개치。
Objective To investigate the clinical efficacy of levonorgestrel intrauterine system in uterus treating adeno-myosis. Methods 84 patients with adenomyosis treated in our hospital from February 2010 to October 2014 were se-lected as research objects,and they were randomly divided into control group and study group,with 42 cases in each group.control group was treated with medicine,study group was treated with levonorgestrel intrauterine system.dysmenor-rhea improvement,uterine volume,serum CA125,hemoglobin and clinical efficacy before and after treatment were com-pared between two groups. Results The total marked rate in study group was 88.1%,while in control group,it was 69.0%with statistical difference (P<0.05),symptoms of dysmenorrheal,decreased serum CA125 in study group was better than that in control group (P<0.05). Conclusion Levonorgestrel intrauterine system placed in the uterus adenomyosis treat-ment is effective and safe,which has a high clinical value.